Form 4: Evolent Health Director Peter Grua Increases Stake with $99,470 Purchase

Director Peter Grua of Evolent Health, Inc. reports purchasing 11,040 shares of Class A Common Stock at an average price of $9.01 on March 6, 2025, increasing his total holdings.

Summary

• On March 6, 2025, Peter J. Grua, a director of Evolent Health, Inc., purchased 11,040 shares of Class A Common Stock.
• The purchase was made at a weighted average price of $9.01 per share, with individual transactions ranging from $8.74 to $9.34.
• Following the transaction, Grua directly owns 18,749 shares of Class A Common Stock.
• Additionally, Grua indirectly owns 41,919 shares through the Peter J. Grua 2004 Revocable Trust.
• The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth in this footnote, upon request.

Sentiment

Score: 6

Explanation: A director purchasing shares is generally a positive signal, suggesting confidence in the company's prospects. However, without additional context, the impact is moderate.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Comparison to Industry Standards

• Comparing Peter Grua's transactions to similar insider transactions at companies like Oak Street Health (before its acquisition by CVS Health) or Agilon Health, which also operate in the value-based care and healthcare technology space, could provide context.
• Analyzing the size and frequency of insider buys and sells at these comparable companies can help determine whether Grua's purchase is a typical or noteworthy event.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates